J B Chemicals & Pharmaceuticals Limited (JB Pharma) is an integrated, publicly-listed pharmaceutical organization established in 1976, with a focus on supplying affordable, quality products both in India and internationally. The company is trusted by healthcare professionals globally and stands as one of India's leading pharmaceutical companies.
J B Chemicals & Pharmaceuticals Limited was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976. The JB Pharma story is one of passion and performance, with humble beginnings more than 4 decades ago.
J B Chemicals is a holistic pharmaceutical company that has varied products and dosage forms across therapeutic categories. While the company is a big player in gastroenterology, hypertension, and dermatology, it has also entered newer therapeutic categories like nephrology, respiratory, virology, diabetes, and Nicotine Replacement Therapy (NRT).
The company's product portfolio is comprehensive and diverse. J B Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI.
It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms.
The company operates 7 state-of-the-art manufacturing units in Gujarat, India, which have over 40 global accreditations including US-FDA, EU-GMP and South Africa – SAHPRA. J B Chemicals specializes in manufacturing of medicated and herbal lozenges, with all its lozenges (herbal, medicated and soft-centered) available in sugar and sugar-free options.
The company maintains a direct presence in Russia and South Africa, along with distributor relationships in the United States and various markets throughout Asia, Africa, and Latin America. The revenue split for H1FY24 shows Domestic Formulations contributing 55%, Export Formulations 30%, Contract Manufacturing 13%, and APIs 2%.
J B Chemicals has demonstrated strong financial performance in recent periods. As of the latest data, J B Chemicals & Pharmaceuticals Ltd has a market capitalisation of Rs 26,222 crore.
The company's consolidated net profit for Q4 FY25 rose by 15.5% to ₹145.7 crore, compared to ₹126.2 crore in the same period last year. JB Chemicals' revenue for Q4 FY25 increased by 10.2% to ₹949.5 crore, compared to ₹861.7 crore in Q4 FY24.
JB Chemicals and Pharmaceuticals posted a 21.64 per cent year-on-year increase in net profit during Q3FY25, reaching Rs 162.4 crore, while revenue from operations increased by 14 per cent Y-o-Y to Rs 963.4 crore.
The company reported a turnover of INR 3,149 Cr in FY23. For the year ended 2024, J B Chemicals & Pharmaceuticals Ltd had posted a profit of Rs 552.63 crore on a total income of Rs 3,484.18 crore.
- Revenue: 3,918 Cr, Profit: 660 Cr
- Operating EBITDA was Rs 270 crore in Q3FY25 (YoY growth of 15%) and Rs 846 crore in 9MFY25 (YoY growth of 16%). Operating EBITDA margin improved to 28.1% for Q3FY25 YoY and improved to 28.5% for 9MFY25 YoY.
- The company had a net cash position of Rs 516 crore as of December 31, 2024, with gross debt at Rs 54 crore.
The company's brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The Group's products include metrogyl, rantac (a ranitidine-based formula), and nicardia, a cardiac care medicine.
JB Chemicals & Pharmaceuticals received USFDA approval for Amitriptyline Hydrochloride Tablets in June 2025, boosting its market presence. The company reported a 15.5% rise in Q4 net profit, reinforcing growth prospects in the US market.
Torrent Pharma has offered INR 1,639.18/share to acquire 26% stake in J.B. Chemicals, totaling INR 6,842 crore.
Promoter holding in J B Chemicals & Pharmaceuticals Ltd has gone down to 47.84 per cent as of Mar 2025 from 53.77 per cent as of Jun 2024.
Equitable healthcare is a cause that is close to the company's heart since inception. The company has supported a number of initiatives towards the eradication of malnutrition, upgrading of medical equipments at hospitals, and spreading of healthcare education.
J B Chemicals & Pharmaceuticals continues to strengthen its position as a trusted pharmaceutical company, focusing on innovation, quality, and expanding its global footprint while maintaining strong financial performance and operational excellence.
